Abstract
Finding novel compounds as starting points for optimization is a major challenge in drug discovery research. Fragment-based methods have emerged in the past ten years as an effective way to sample chemical diversity with a limited number of low molecular weight compounds. The structures of the fragments(s) binding to the protein can then be used to design new compounds with increased affinity, specificity and novelty. This article describes the Vernalis approach to fragment based drug discovery, called SeeDs (Structural exploitation of experimental Drug startpoints). The approach includes the design of a fragment library, identification of fragments that bind competitively to a target by ligand-based NMR techniques and protein crystal structures to characterize binding. Fragments that bind are then evolved to hits, either by growing the fragment or by combining structural features from a number of compounds. The process is illustrated with examples from recent medicinal chemistry programmes to discover compounds against the oncology targets Hsp90 and PDK1. In addition, we summarise our experience with using molecular docking calculations to predict fragment binding and anecdotes on the selectivity and binding modes for fragments seen against a range of targets.
Keywords: Structure-based drug discovery, fragment-based drug discovery, drug design, NMR spectroscopy, Hsp90, PDK1
Current Topics in Medicinal Chemistry
Title: The SeeDs Approach: Integrating Fragments into Drug Discovery
Volume: 7 Issue: 16
Author(s): Roderick E. Hubbard, Ben Davis, Ijen Chen and Martin J. Drysdale
Affiliation:
Keywords: Structure-based drug discovery, fragment-based drug discovery, drug design, NMR spectroscopy, Hsp90, PDK1
Abstract: Finding novel compounds as starting points for optimization is a major challenge in drug discovery research. Fragment-based methods have emerged in the past ten years as an effective way to sample chemical diversity with a limited number of low molecular weight compounds. The structures of the fragments(s) binding to the protein can then be used to design new compounds with increased affinity, specificity and novelty. This article describes the Vernalis approach to fragment based drug discovery, called SeeDs (Structural exploitation of experimental Drug startpoints). The approach includes the design of a fragment library, identification of fragments that bind competitively to a target by ligand-based NMR techniques and protein crystal structures to characterize binding. Fragments that bind are then evolved to hits, either by growing the fragment or by combining structural features from a number of compounds. The process is illustrated with examples from recent medicinal chemistry programmes to discover compounds against the oncology targets Hsp90 and PDK1. In addition, we summarise our experience with using molecular docking calculations to predict fragment binding and anecdotes on the selectivity and binding modes for fragments seen against a range of targets.
Export Options
About this article
Cite this article as:
Hubbard E. Roderick, Davis Ben, Chen Ijen and Drysdale J. Martin, The SeeDs Approach: Integrating Fragments into Drug Discovery, Current Topics in Medicinal Chemistry 2007; 7 (16) . https://dx.doi.org/10.2174/156802607782341109
DOI https://dx.doi.org/10.2174/156802607782341109 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanotechnology Versus other Techniques in Improving Drug Dissolution
Current Pharmaceutical Design Medicinal and Therapeutic Potential of Herbs and Plant Metabolites / Extracts Countering Viral Pathogens - Current Knowledge and Future Prospects
Current Drug Metabolism Identification of Antifungal Agents Using Combinatorial Approach: An Overview$
Current Medicinal Chemistry - Anti-Infective Agents Epidermal Growth Factor Receptor-Targeted Therapy of Colorectal Cancer with Panitumumab
Current Cancer Therapy Reviews A Novel and Facile Synthesis of N-Substituted 8-hydroxybenzo[g] chromeno[4, 3-b]indol-6(13H)-ones by a Nenitzescu Reaction
Letters in Organic Chemistry Laboratory Diagnosis and Therapy of Invasive Fungal Infections
Current Drug Targets Anti-Microbial
Current Bioactive Compounds Grape Phytochemicals and Vitamin D in the Alleviation of Lung Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Design, Synthesis and Biological Evaluation of a Library of Thiocarbazates and Their Activity as Cysteine Protease Inhibitors
Combinatorial Chemistry & High Throughput Screening DBU Catalysis: An Efficient Synthetic Strategy for 5,7-disubstituted-1,2,4- triazolo[1,5-a]pyrimidines
Current Organic Synthesis <i>In Silico</i> Identification of New Anti-SARS-CoV-2 Agents from Bioactive Phytocompounds Targeting the Viral Spike Glycoprotein and Human TLR4
Letters in Drug Design & Discovery A Comparison of Methods for Pharmacophore Generation with the Catalyst Software and their Use for 3D-QSAR Application to a Set of 4-Aminopyridine Thrombin Inhibitors
Mini-Reviews in Medicinal Chemistry An Effective COVID-19 CT Image Denoising Method Based on a Deep Convolutional Neural Network
Recent Advances in Computer Science and Communications COVID-19-associated Coagulopathy: Role of Vitamins D and K
Current Pharmaceutical Biotechnology Small Molecule 11β- Hydroxysteroid Dehydrogenase Type 1 Inhibitors
Current Topics in Medicinal Chemistry Pleiotropic Effects of Nitric Oxide on SARS-CoV-2 Infections
Coronaviruses Epidemiology of Vitamin D and Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Bosentan in Pediatric Patients with Pulmonary Arterial Hypertension
Current Vascular Pharmacology Plausible Improvements for Selective Targeting of Dopamine Receptors in Therapy of Parkinson’s Disease
Mini-Reviews in Medicinal Chemistry An Insight of Novel Pharmacological Therapies in Hypertrophic Cardiomyopathy
Medicinal Chemistry